NASDAQ$ZVRA
Zevra Therapeutics Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
KemPharm reported financial results for the second quarter ended June 30, 2020.
KemPharm reported revenue of $6.9 million, driven by a $5.0 million milestone payment and $1.9 million from research and development services. Net income for the quarter was $0.9 million, or $0.01 per share, compared to a net loss of $9.3 million for the same period in 2019. Cash and cash equivalents increased by $4.0 million to $6.6 million as of June 30, 2020.
- FDA accepted the New Drug Application (NDA) for KP415.
- Received the $5 million milestone payment upon FDA’s acceptance of the KP415 NDA.
- Corium, Inc. will lead all commercialization activities for KP415.
- Two U.S. patents governing KP415 and KP484 were issued with an expiration date of December 9, 2037.
Headline financials
Revenue & EPS history
Zevra · Revenue · Quarterly
$6.91M
Forward guidance
Based on the Company’s current operating forecast, the Company believes that its expected revenues and existing resources are sufficient to continue operations past the potential March 2, 2021 PDUFA date for the KP415 NDA and up to the debt maturity date of March 31, 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2020
-0.2%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+3.8%
Avg return
30 days after
45%
20 / 44 earnings
Positive
+35.2%
Q2 2015
Best reaction
-19.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.0% | +1.6% | -0.1% | |
| Q4 2025 | +21.3% | +9.4% | +6.5% | |
| Q3 2025 | -9.8% | -6.4% | -13.5% | |
| Q1 2025 | +3.0% | +2.7% | +8.3% | |
| Q4 2024 | -2.1% | -2.1% | +10.5% | |
| Q3 2024 | -3.5% | -3.8% | -5.8% | |
| Q2 2024 | +2.6% | +8.2% | +11.5% | |
| Q1 2024 | -2.7% | -5.5% | -10.1% | |
| Q4 2023 | -13.3% | -13.9% | -23.9% | |
| Q3 2023 | -3.5% | -9.0% | +12.7% | |
| Q2 2023 | +3.8% | -4.2% | -2.7% | |
| Q1 2023 | +3.1% | +27.7% | +37.1% | |
| Q4 2022 | -19.4% | -22.8% | +4.9% | |
| Q3 2022 | -18.3% | -17.6% | -19.7% | |
| Q2 2022 | -5.4% | -14.6% | -4.3% | |
| Q1 2022 | +2.0% | +15.9% | +9.5% | |
| Q4 2021 | -4.7% | -1.3% | -15.3% | |
| Q3 2021 | -0.1% | -2.1% | -9.9% | |
| Q2 2021 | -9.4% | -7.2% | -7.6% | |
| Q1 2021 | +3.4% | +10.8% | +65.9% | |
| Q4 2020 | +19.5% | +14.4% | -8.3% | |
| Q3 2020 | -5.2% | +6.2% | +83.0% | |
| Q2 2020 | +8.7% | +46.8% | +48.9% | |
| Q1 2020 | -13.5% | -21.2% | -27.3% | |
| Q4 2019 | -0.9% | -8.5% | -30.9% | |
| Q3 2019 | +11.3% | -5.5% | -21.6% | |
| Q2 2019 | -15.8% | -18.3% | -25.8% | |
| Q1 2019 | +4.9% | +9.0% | +17.2% | |
| Q4 2018 | -14.6% | -16.2% | -32.4% | |
| Q3 2018 | -1.9% | -6.9% | +8.4% | |
| Q2 2018 | +5.5% | +0.0% | +13.7% | |
| Q1 2018 | +16.8% | +23.8% | +35.6% | |
| Q4 2017 | -9.9% | -13.2% | -29.1% | |
| Q3 2017 | +1.4% | +0.0% | +1.4% | |
| Q2 2017 | +8.5% | -8.5% | +9.3% | |
| Q1 2017 | +0.0% | +3.8% | +2.5% | |
| Q4 2016 | +9.7% | +18.1% | +31.9% | |
| Q3 2016 | +3.8% | +3.8% | -3.8% | |
| Q2 2016 | +0.0% | +7.7% | +22.0% | |
| Q1 2016 | -15.7% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | -8.8% | — | — | |
| Q2 2015 | +35.2% | — | — | |
| Q1 2015 | -2.7% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro